Bio-Rad Laboratories, Inc. (BIO) Income Statement
BIO 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsBIO revenue and net income
Where BIO's revenue goes
2025Each bar shows an amount and its share of revenue. BIO kept 29.4% of revenue as net income.
BIO profit margins
BIO growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +0.7% | −2.7% | +0.3% | +2.5% |
| Gross profit | −2.6% | −5.0% | −1.3% | +1.8% |
| Operating income | +0.6% | −17.6% | −8.5% | +5.0% |
| Net income | — | — | −27.6% | +21.0% |
| EPS (diluted) | −3.8% | −11.3% | −1.2% | +9.2% |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
BIO quarterly EPS vs estimates
Bio-Rad Laboratories beat the analyst EPS estimate in 6 of the last 8 quarters. Next report: November 4, 2026 (estimate $2.61).
BIO income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.58B | $2.57B | $2.67B | $2.80B | $2.92B | $2.55B | $2.31B | $2.29B | $2.16B | $2.07B |
| Cost of revenue | $1.24B | $1.19B | $1.24B | $1.23B | $1.28B | $1.11B | $1.05B | $1.07B | $972.8M | $930.1M |
| Gross profit | $1.34B | $1.38B | $1.43B | $1.57B | $1.64B | $1.44B | $1.26B | $1.22B | $1.19B | $1.14B |
| Research & development | $256.9M | $295.9M | $247.4M | $256.9M | $260.6M | $217.8M | $202.7M | $199.2M | $250.3M | $205.9M |
| Sales, general & admin | $844.3M | $814.0M | $846.8M | $827.8M | $879.6M | $800.3M | $824.6M | $836.3M | $808.9M | $816.7M |
| Total operating expenses | $1.08B | $1.11B | $1.09B | $1.08B | $1.14B | $1.02B | $1.03B | $1.03B | $1.06B | $1.02B |
| Operating income | $270.5M | $269.0M | $337.8M | $482.6M | $500.3M | $421.3M | $229.7M | −$108.6M | $116.7M | $53.2M |
| Interest income | $95.5M | $82.0M | $96.4M | $58.0M | $4.92B | $4.49B | $30.5M | $26.6M | $19.1M | $14.7M |
| Interest expense | $49.0M | $48.9M | $49.4M | $38.1M | $1.6M | $21.9M | $23.4M | $24.0M | $23.0M | $23.4M |
| Income before taxes | $995.5M | −$2.34B | −$850.1M | −$4.70B | $5.45B | $4.92B | $2.26B | $507.4M | $97.8M | $41.6M |
| Income taxes | $235.6M | −$498.3M | −$212.8M | −$1.08B | $1.19B | $1.10B | $502.4M | $146.4M | −$16.9M | $13.4M |
| Net income | $759.9M | −$1.84B | −$637.3M | −$3.63B | $4.25B | $3.81B | $1.76B | $361.0M | $114.7M | $28.1M |
| EBITDA | $1.21B | −$2.14B | −$654.8M | −$4.53B | $5.59B | $5.08B | $2.46B | $674.7M | $269.5M | $206.4M |
| EPS (diluted) | $9.92 | $10.31 | $11.77 | $14.23 | $15.67 | $10.53 | $7.15 | $5.68 | $2.00 | $0.95 |
| Gross margin | 52.0% | 53.7% | 53.4% | 55.9% | 56.1% | 56.5% | 54.4% | 53.5% | 55.0% | 55.0% |
| Operating margin | 10.5% | 10.5% | 12.6% | 17.2% | 17.1% | 16.6% | 9.9% | −4.7% | 5.4% | 2.6% |
| Net margin | 29.4% | −71.9% | −23.9% | −129.5% | 145.6% | 149.8% | 76.1% | 15.8% | 5.3% | 1.4% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $651.0M | $592.1M | $693.2M | $653.0M | $651.6M | $585.4M | $667.5M | $649.7M | $638.5M | $610.8M | $681.2M | $632.1M |
| Cost of revenue | $305.2M | $282.7M | $348.0M | $309.6M | $306.3M | $279.4M | $325.6M | $293.8M | $282.8M | $284.4M | $315.3M | $296.4M |
| Gross profit | $345.8M | $309.4M | $345.2M | $343.4M | $345.3M | $306.0M | $341.9M | $355.9M | $355.1M | $326.5M | $365.9M | $335.7M |
| Research & development | $61.2M | $62.9M | $65.7M | $71.3M | $60.5M | $73.5M | $79.6M | $91.0M | $59.3M | $64.0M | $62.2M | $43.5M |
| Sales, general & admin | $212.0M | $212.4M | $221.0M | $206.8M | $207.7M | $208.8M | $204.0M | $200.4M | $194.7M | $214.9M | $207.1M | $201.2M |
| Total operating expenses | $273.2M | $275.3M | $282.3M | $278.1M | $268.2M | $282.3M | $283.6M | $291.4M | $253.6M | $274.5M | $268.1M | $244.7M |
| Operating income | $72.6M | $34.1M | $61.9M | $66.4M | $77.1M | $23.7M | $58.3M | $64.5M | $101.5M | $52.0M | $97.8M | $90.9M |
| Interest income | $22.3M | $21.0M | $31.0M | $13.7M | $14.7M | $36.2M | $15.9M | $15.5M | $16.6M | $34.0M | $16.8M | $17.3M |
| Interest expense | $12.1M | $12.3M | $12.1M | $12.3M | $12.6M | $12.0M | $12.2M | $12.2M | $12.3M | $12.3M | $12.4M | $12.4M |
| Income before taxes | $542.1M | −$689.8M | $929.2M | −$431.1M | $414.0M | $83.4M | −$908.9M | $861.6M | −$2.79B | $491.1M | $428.4M | $137.1M |
| Income taxes | $170.7M | −$162.7M | $209.2M | −$89.2M | $96.2M | $19.4M | −$193.1M | $208.4M | −$620.8M | $107.2M | $78.7M | $30.8M |
| Net income | $371.4M | −$527.1M | $720.0M | −$341.9M | $317.8M | $64.0M | −$715.8M | $653.2M | −$2.17B | $383.9M | $349.7M | $106.3M |
| EBITDA | $542.1M | −$636.6M | $983.8M | −$374.6M | $477.2M | $133.5M | −$847.4M | $922.9M | −$2.73B | $551.2M | $493.8M | $197.6M |
| EPS (diluted) | $2.62 | $1.89 | $2.51 | $2.26 | $2.61 | $2.54 | $2.90 | $2.01 | $3.11 | $2.29 | $3.10 | $2.33 |
| Gross margin | 53.1% | 52.3% | 49.8% | 52.6% | 53.0% | 52.3% | 51.2% | 54.8% | 55.6% | 53.4% | 53.7% | 53.1% |
| Operating margin | 11.2% | 5.8% | 8.9% | 10.2% | 11.8% | 4.0% | 8.7% | 9.9% | 15.9% | 8.5% | 14.4% | 14.4% |
| Net margin | 57.1% | −89.0% | 103.9% | −52.4% | 48.8% | 10.9% | −107.2% | 100.5% | −339.2% | 62.9% | 51.3% | 16.8% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in BIO's financial statements (latest annual report filed February 13, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
BIO financial results
In fiscal year 2025 (ended December 31, 2025), Bio-Rad Laboratories reported revenue of $2.6 billion, up 0.7% from the year before. It had net income of $759.9 million, a net profit margin of 29.4%. Diluted earnings per share came to $9.92. Over five years revenue grew at an average rate of 0.3% a year.
See the BIO stock overview for the latest quote and news, or the BIO chart for price history and technical indicators.
BIO income statement FAQ
What is Bio-Rad Laboratories's annual revenue?
Bio-Rad Laboratories reported total revenue of $2.6 billion for fiscal year 2025, which ended on December 31, 2025. That was up 0.7% from $2.6 billion the previous year.
Is Bio-Rad Laboratories profitable?
Yes. Bio-Rad Laboratories reported net income of $759.9 million in fiscal 2025, a net profit margin of 29.4%; its operating margin was 10.5%.
What is Bio-Rad Laboratories's gross margin?
Bio-Rad Laboratories's gross margin was 52.0% in fiscal 2025: for every $100 of revenue, Bio-Rad Laboratories kept $52 after the direct cost of its products and services.
How much does Bio-Rad Laboratories spend on research and development?
Bio-Rad Laboratories spent $256.9 million on research and development in fiscal 2025, 9.9% of revenue.
How fast is Bio-Rad Laboratories growing?
Revenue grew 0.3% a year on average over the last five fiscal years, from $2.5 billion to $2.6 billion.
What are Bio-Rad Laboratories's earnings per share?
Bio-Rad Laboratories earned $9.92 per diluted share in fiscal 2025, compared with $10.31 a year earlier.
When will Bio-Rad Laboratories report its next earnings?
Bio-Rad Laboratories is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 after the market closes.
When does Bio-Rad Laboratories's fiscal year end?
Bio-Rad Laboratories's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 13, 2026.